Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The pancreatic cancer pipeline is gaining momentum as more than 170 companies push forward over 200 therapies in development. DelveInsight's 2026 Pancreatic Cancer Pipeline Insight maps a robust ecosystem, including a May 28 phase II trial by Shandong Suncadia Medicine of HRS-7058, a KRAS G12C inhibitor, in patients who have failed prior therapy. On May 16, 2026, Daiichi Sankyo advanced a phase II study of DX-8951f for metastatic pancreatic cancer not previously treated or resistant to chemotherapy. Leading companies span Shanghai Chia Tai Tianqing, Oncotelic, Golden Biotechnology, Cantargia AB, Marker Therapeutics, ImmunityBio, Merck & Co., Eisai, and others. Promising therapies highlighted include Gemcitabine-based regimens such as Gemcitabine plus TS-1, Gemcitabine and regimens like FOLFOX or NC-6004, while the report notes pancreatic cancer remains among the deadliest cancers with five-year survival often in the single digits.